Results of a phase II study examining ibrutinib combined with venetoclax for first line treatment of CLL. (Abstract only)
Home / Resource Library / Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial